Upregulation of Striatal Adenosine A2A Receptor mRNA in 6-Hydroxydopamine-Lesioned Rats Intermittently Treated with L-DOPA

Synapse

Volumn 52, Issue 3, 2004, Pages 218-222

  Tomiyama, Masahiko ^a   Kimura, Tamaki ^a   Maeda, Tetsuya ^a   Tanaka, Hiroyasu ^a   Kannari, Kazuya ^a   Baba, M Asayuki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Dopamine; Dyskinesia; Parkinson's disease; Priming; Striatum

Indexed keywords

ADENOSINE A2A RECEPTOR; DOPAMINE; LEVODOPA; MESSENGER RNA; OXIDOPAMINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; UPREGULATION;

ANIMALS; APOMORPHINE; AUTORADIOGRAPHY; DOPAMINE AGENTS; DOPAMINE AGONISTS; LEVODOPA; MALE; NEOSTRIATUM; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RNA, MESSENGER; STEREOTYPED BEHAVIOR; SYMPATHECTOMY, CHEMICAL; SYMPATHOLYTICS; UP-REGULATION;

EID: 2342581472     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20011     Document Type: Article

References (30)

1. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61:293-296.
2. Bergman H, Wichmann T, DeLong MR. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
3. 2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 44:166-174.
4. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147.
5. 2A adenosine receptors. J Neurosci 22:1054-1062.
6. Fredholm BIB, Ap IJ, Jacobson KA, Klotz KN, Linden J. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
7. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677.
8. Henry B, Brotchie JM. 1996. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 9:149-158.
9. Henry B, Crossman AR, Brotchie JM. 1998. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:334-342.
10. Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A, Agid Y, Chase TN. 1989. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25:473-478.
11. 2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J Neural Transm 107:851-859.
12. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513.
13. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-327.
14. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408:249-255.
15. 2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.
16. Maeda T, Kannari K, Suda T, Matsunaga M. 1999. Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum. Brain Res 817:185-191.
17. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, Suda T. 2003. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343:17-20.
18. Morelli M, Fenu S, Pinna A, Di Chiara G. 1994. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 251:21-25.
19. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100:53-62.
20. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
21. Perier C, Marin C, Bonastre M, Tolosa E, Hirsch EC. 2002. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. Eur J Neurosci 16:2236-2240.
22. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233-238.
23. 2A receptor mRNA by dopamine denervation. Eur J Pharmacol 446: 75-82.
24. Schiffmann SN, Vanderhaeghen JJ. 1993. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080-1087.
25. 2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 12:4033-4037.
26. 2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Nenroscience 80:1171-1185.
27. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. 1999. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631-634.
28. Tomiyama M, Rodriguez-Puertas R, Cortes R, Christnacher A, Sommer B, Pazos A, Palacios JM, Mengod G. 1996. Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization. Neuroscience 75:901-915.
29. Westin JE, Andersson M, Lundblad M, Cenci MA. 2001. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14:1171-1176.
30. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. 2000. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12:1096-1104.